The BioHub: The Top Voices in Biotech

In this episode of The BioHub Podcast, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.

Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.

In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.

They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.

Today’s guest brings one of the broadest and most thoughtful perspectives in neuroscience, spanning clinical practice, drug development, investing, and company building.
Dr. Spyros Papapetropoulos is a neurologist, neuroscientist, and biotech leader who has spent his career at the intersection of science, medicine, and innovation. With deep experience across both large pharma and emerging biotech, he has built a reputation for translating complex neuroscience into clear strategic direction - helping shape how new therapies move from idea to impact.
Over the years, Spyros has worked across multiple dimensions of the CNS ecosystem, from research and development through to leadership, investing, and advising. His work has given him a unique vantage point on what it really takes to build successful neuroscience companies, where the field is heading, and why progress in CNS demands a different kind of thinking.
He is also the author of Mind Odyssey, a book that reflects on neuroscience, innovation, and the future of brain health - themes that closely mirror the work he continues to do across the biotech landscape today.
In this conversation, we explore Spyros’ journey through neuroscience, his view on the current state of the CNS biotech ecosystem, where drug development is heading next, and what it takes to build companies, teams, and ideas that can genuinely move the field forward.

Today’s guest brings a rare blend of medicine, science, and strategy to the frontlines of biotech innovation.
Dr. Megan McGill is a physician-scientist and biotech leader with over two decades of experience spanning clinical medicine, neuroscience research, and drug development. Trained as both an MD and PhD, her work has focused deeply on understanding the brain—particularly the mechanisms behind neurodegenerative diseases like Parkinson’s.
But Megan didn’t stop at the lab or the clinic. She’s also worked at the highest levels of strategy consulting with McKinsey & Company, and held leadership roles at cutting-edge biotech firms like Regenxbio and BridgeBio, helping translate scientific breakthroughs into real therapies for patients.
Today, she serves as CEO of Brenig Therapeutics, where she’s leading efforts to develop next-generation, AI-enabled treatments targeting the underlying biology of neurological disease.
In this conversation, we’ll explore her journey from medicine to biotech leadership, the future of drug development, women in leadership positions and what it takes to turn scientific insight into life-changing innovation.

In this episode of The Biohub Podcast, Amber sits down with Tess Bevers CEO and Founder of Novogaia, a company combining AI and mass spectrometry to discover new drug molecules from fungi.
We explore why fungi remain one of the most underexplored sources of chemistry in nature, the historical bottlenecks in natural product drug discovery, and how new advances in AI are helping researchers prioritise which molecules could actually become viable drugs.Tess also shares how Novogaia is building its discovery platform, why focus matters in biotech, and what’s driving the company’s move from London to San Francisco.

Welcome to another episode of The BioHub.
Today I’m joined by Jason Tardio —COO of Immunic Therapeutics, a clinical stage biotech for oral small molecule therapies for chronic inflammatory and autoimmune diseases.

In this episode we explore Jason's awesome background, from starting as a sales rep and climbing the ladder into his position today, as COO.